Zhejiang MartianlT Technology Co., Ltd. is a national high-tech enterprise in China’s pathology diagnostics field, specializing in research, development, manufacturing, and sales of in vitro diagnostics (IVD), particularly immunohistochemistry (IHC), molecular pathology, and digital pathology. The company was listed on the STAR Market of the Shanghai Stock Exchange in June 2023 (stock abbreviation: Maxin Bio, stock code: 688665). Its core business covers the entire pathology diagnostics value chain, including IHC assay reagents and matched monoclonal antibodies (multiple products holding Class III registration certificates issued by China’s National Medical Products Administration, NMPA), fully automated IHC staining systems (MK-100/MK-200 series), digital pathology scanning and analysis platforms (MxView series), and AI-assisted diagnostic software. Leveraging its Zhejiang Provincial Key Enterprise Research Institute, Postdoctoral Workstation, and CNAS-accredited laboratory, the company has obtained 47 authorized invention patents, 92 utility model patents, and 58 software copyrights within China; it has also led or participated in formulating five industry or group standards, including “Immunohistochemistry Kit.” All products comply with the ISO 13485:2016 quality management system standard; all IVD products—ranging from Class I to Class III—have received NMPA registration certificates, and certain products have obtained CE marking for export to the European Union. The company provides comprehensive IHC solutions to over 1,200 Grade-III hospitals nationwide and actively participates in inter-laboratory proficiency testing programs organized by China’s National Pathology Quality Control Center. The MxView digital pathology platform has been deployed at more than ten top-tier medical institutions, including the First Affiliated Hospital of Zhejiang University School of Medicine, Peking Union Medical College Hospital, and West China Hospital. Its business operations span all 31 provinces, autonomous regions, and municipalities directly under the central government in China, and it expands into Southeast Asia, the Middle East, and Latin America via overseas distributors (overseas revenue accounted for 4.2% of total revenue in 2023). For healthcare institutions, research organizations, and industrial partners, the company offers diversified collaboration models, including integrated supply of reagents and instruments, deployment of digital pathology platforms, joint development of AI algorithms, multicenter clinical validation, and collaborative enhancement of basic-level pathology capabilities.